Matisse Capital Fulcrum Therapeutics, Inc. Transaction History
Matisse Capital
- $206 Million
- Q2 2025
A detailed history of Matisse Capital transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Matisse Capital holds 26,100 shares of FULC stock, worth $170,694. This represents 0.09% of its overall portfolio holdings.
Number of Shares
26,100
Previous 96,717
73.01%
Holding current value
$170,694
Previous $278,000
35.61%
% of portfolio
0.09%
Previous 0.15%
Shares
4 transactions
Others Institutions Holding FULC
# of Institutions
123Shares Held
52.3MCall Options Held
48.9KPut Options Held
13.8K-
Ra Capital Management, L.P. Boston, MA10.2MShares$66.9 Million0.61% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$34.3 Million3.64% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.07MShares$33.1 Million0.64% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.82MShares$31.5 Million0.63% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$31.4 Million0.0% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $340M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...